A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515755-37-00

Acronym

ACHILES

Enrollment

195

Registered

2024-10-11

Start date

2018-07-31

Completion date

Unknown

Last updated

2024-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limited disease small-cell lung cancer

Brief summary

Overall survival

Detailed description

Best response rates (best response observed through the whole study period), Progression free survival, Toxicity, Health related quality of life

Interventions

DRUGTecentriq 1 200 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Best response rates (best response observed through the whole study period), Progression free survival, Toxicity, Health related quality of life	—

Countries

Denmark, Lithuania, Netherlands, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026